<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03134534</url>
  </required_header>
  <id_info>
    <org_study_id>RTS-002</org_study_id>
    <nct_id>NCT03134534</nct_id>
  </id_info>
  <brief_title>Robot-assisted vs VATS Lobectomy for NSCLC</brief_title>
  <acronym>RVlob</acronym>
  <official_title>The Study of Robotic-assisted Thoracoscopic Surgery Versus Video-assisted Thoracoscopic Surgery Lobectomy for Non-small Cell Lung Cancer on Short-term and Long-term Outcomes (RVlob)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Robot-assisted thoracoscopic surgery (RATS) was widely used in thoracic surgery, the surgical&#xD;
      safety and feasibility of RATS lobectomy for NSCLC has been confirmed. However, the&#xD;
      oncological long-term outcomes of RATS lobectomy has not been studied by randomized&#xD;
      controlled trial, the purpose of this study is to determine whether RATS lobectomy would be&#xD;
      as effective as VATS lobectomy on short-term and long-term outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Video-assisted thoracoscopic surgery (VATS) lobectomy is recommended for non small cell lung&#xD;
      cancer (NSCLC) with surgical indications in China, its oncological long-term outcomes has&#xD;
      been widely approved. As a new form of VATS, robot-assisted thoracoscopic surgery (RATS) was&#xD;
      widely used in thoracic surgery, the 3D vision and flexible robot arm were helpful for&#xD;
      surgeons to perform precise operations, and RATS was reported to bring extra benefits to&#xD;
      patients. The surgical safety and feasibility of RATS lobectomy for NSCLC has been confirmed.&#xD;
      However, the oncological long-term outcomes of RATS lobectomy has not been studied by&#xD;
      randomized controlled trial. so we designed this randomized controlled trial to determine&#xD;
      whether RATS lobectomy would be as effective as VATS lobectomy on short-term and long-term&#xD;
      outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year overall survival (OS)</measure>
    <time_frame>3 year after surgery</time_frame>
    <description>OS at 3 year after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymph node counts</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>overall lymph node counts, number of stations dissected, and number of lymph nodes in each lymph node station</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year disease-free survival (DFS)</measure>
    <time_frame>3 year after surgery</time_frame>
    <description>DFS at 3 year after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival (OS)</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>OS at 1 year after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year disease-free survival (DFS)</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>DFS at 1 year after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 rate</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>R0 radical rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>margin state</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>positive margin rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative time</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>the time of operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood loss</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>blood loss in the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>conversion rate</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>the rate of conversion to open surgery in the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative accident event</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>the accident event happened in operative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>30-day mortality after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay (LOS)</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>length of stay in hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>mainly include: pneumonia, arrhythmia, incision infection, vocal cord paralysis, trachea cannula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QOL) at 3 month</measure>
    <time_frame>at 3 month after surgery</time_frame>
    <description>QOL, WHOQOL-BREF</description>
  </secondary_outcome>
  <other_outcome>
    <measure>total hospitalization expenditures</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>cost in hospital</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Pulmonary Neoplasm</condition>
  <arm_group>
    <arm_group_label>VATS group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgical procedure: VATS lobectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RATS group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgical procedure: RATS lobectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VATS lobectomy</intervention_name>
    <description>a minimal invasive surgical types for NSCLC: VATS lobectomy</description>
    <arm_group_label>VATS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RATS lobectomy</intervention_name>
    <description>a minimal invasive surgical types for NSCLC: RATS lobectomy</description>
    <arm_group_label>RATS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. surgical indication for lobectomy;&#xD;
&#xD;
          2. minimal invasive surgery;&#xD;
&#xD;
          3. ASA (American Society of Anesthesiologists) stage: I-III;&#xD;
&#xD;
          4. sign the informed consent. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. benign tumor or nodule;&#xD;
&#xD;
          2. present of other malignancy;&#xD;
&#xD;
          3. preoperative chemotherapy, radiotherapy, targeted therapy. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>He-Cheng Li, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai JiaoTong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 15, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Hecheng Li M.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>lobectomy</keyword>
  <keyword>robot-assisted thoracoscopic surgery</keyword>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

